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The porphyrias are a group of disorders (Table 1) associated with 
inherited or acquired defects in the enzymes of the haem biosynthetic 
pathway (Fig. 1). South Africa has the highest prevalence of porphyria 
in the world, the consequence of a founder effect which has led to one 
form of porphyria, variegate porphyria (VP), becoming uniquely and 
locally common.1,2
Geoffrey Dean, a physician working in Port Elizabeth in the 
1950s, identified a large number of families of Dutch descent in the 
Eastern Cape with a disorder, apparently inherited, which manifested 
as photocutaneous disease and an alarming tendency to develop a 
severe and sometimes fatal crisis, characterised by abdominal pain, 
red urine and paralysis, particularly in response to medication such 
as barbiturates. Working with Hubert Barnes of the South African 
Institute for Medical Research in Johannesburg, he identified this 
illness as a disorder of porphyrin metabolism, and later showed that 
it represented a previously unrecognised form of porphyria, which 
he named VP. Dean subsequently traced the origins of VP to the 
marriage of a Dutch couple in Cape Town in 1688.3
The Faculty of Health Sciences of the University of Cape Town 
(UCT) celebrates its centenary this year and has been active in the 
study of porphyria for more than half of that century. Indeed, one 
precocious fifth-year medical student, Lennox Eales, described an 
early case of porphyria in a paper published in the UCT medical 
student journal, I’nyanga, in 1939.1
The early years
After graduation, Eales joined the Department of Medicine, 
subsequently rising to occupy the Chair of Clinical Medicine. 
He developed a passion for the study of porphyria and published 
extensively on the subject. In 1962 he established a porphyria 
research group, supported by the Council for Scientific and 
Industrial Research, through his Renal Metabolic Research Group, 
which received international recognition. This research unit was 
subsequently supported by the South African Medical Research 
Council (MRC) through the UCT-MRC Porphyria Research Group 
housed within the Department of Medicine.
Eales, together with a small international group of pioneering scientists 
and clinicians, laid the foundations of porphyrinology, a composite 
field which spans the study of both the science of haem biosynthesis 
and the clinical disorder. This group collaborated during an exciting 
period in which the link between the porphyrias and disturbances in 
mammalian haem synthesis was first established and characterised. This 
link underpins all subsequent work on the biochemical and metabolic 
basis of these disorders and their clinical consequences.
A subset of the porphyrias, including VP, carries the risk of an 
acute attack, a metabolic crisis characterised by severe neurovisceral 
dysfunction that may result in paralysis and death. Many drugs 
that undergo hepatic metabolism have the capacity to induce 
haem synthesis and, in the patient with VP, the resulting increase 
in porphyrins and their precursors may precipitate the acute 
attack, with potentially fatal consequences. This property is termed 
porphyrogenicity. Eales and his group were active in investigating 
porphyrogenicity, developing laboratory-based experimental 
systems in which the porphyrogenicity of specific drugs might 
be examined, and documenting clinical outcomes in patients 
exposed to specific drugs. They produced the earliest drug safety 
recommendations, which found international acceptance, and the 
drug lists that followed contributed greatly to the improved survival 
of porphyria patients.4
Some of the earliest international conferences on porphyrins 
and porphyrias, in 1963 and 1971, were hosted at UCT, and 83 
publications were produced in the years leading up to Eales’s 
retirement in 1982. A number of clinicians and scientists were 
trained in Eales’s laboratory and subsequently received international 
recognition for their contributions to the study of porphyria and the 
clinical care of patients.*
The past 30 years
The MRC-UCT Liver Research Centre
Under the leadership of Ralph Kirsch, who succeeded Eales in 
the Chair of Clinical Medicine, the Porphyria Research Unit was 
incorporated into the UCT-MRC Liver Research Centre. Eales’s legacy 
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continued, combining research into the basic and clinical aspects 
of porphyrinology with excellence in patient care. International 
conferences were held in Cape Town in 1996 and 2005, and a 
further 71 porphyria-related articles have emanated from the Centre, 
bringing the total to 152.
That VP is related causally to deficient activity in the penultimate 
enzyme of the haem biosynthetic pathway, protoporphyrinogen 
oxidase (PPOX), was first shown by Brenner and Bloomer in 1980.5 
One of us (PNM) subsequently confirmed that VP is unequivocally 
associated with a 50% deficiency in PPOX activity and that this 
deficiency results from a loss of activity of the enzyme through mutated 
structural encoding in the gene, rather than a defect in its synthesis 
or regulation. Important follow-on work provided the answer to an 
otherwise puzzling question: why VP and hereditary coproporphyria 
(HCP) are associated with acute elevations in δ-aminolaevulinic 
acid (ALA) and porphobilinogen (PBG) and thus the acute attack, 
whereas porphyria cutanea tarda (PCT) is not, even though the 
enzymatic defect in PCT occurs more proximally in the haem 
biosynthetic pathway (Fig. 1). We showed that this probably results 
from the competitive inhibition of hydroxymethylbilane synthase 
by coproporphyrinogen and protoporphyrinogen, substrates which 
accumulate in VP and HCP.6 Uroporphyrinogen, which accumulates 
in PCT, appears not to share this ability. Attempts to purify human 
and porcine PPOX in our laboratory proved unsuccessful; related 
biochemical work on the kinetics of this enzyme did however provide 
insights into the functioning of this enzyme.
Much of our work has been performed in collaboration with 
Professors Harry Dailey of the University of Georgia, USA, George 
Elder of the University of Cardiff, UK, and Jean-Charles Deybach 
of the Centre Français des Porphyries in Paris, France. Collaborative 
work with Dailey’s group resulted in the identification, cloning and 
publication of a mammalian PPOX gene sequence, and subsequently 
in the identification of the first mutation associated with VP: the 
R59W mutation.2 We demonstrated that 95% of South African 
families with VP carry this mutation, although a small number 
do not. A critical role for DNA testing in the diagnosis of VP in 
South Africa was thus established, since inheritance of the R59W 
mutant gene, easily confirmed by polymerase chain reaction and 
restriction digest, has a high sensitivity for VP in South Africa. This 
has greatly increased the speed and accuracy of diagnosis,1,7 and has 
subsequently allowed us to determine the sensitivity and specificity 
of more established biochemical tests for porphyria, the penetrance 
of VP,8 and to implement evidence-based, efficient algorithms for 
the laboratory diagnosis of porphyria.7 The ability to accurately 
determine the presence of VP has also allowed us to define the 
spectrum of clinical presentation of VP more precisely. Contrary to 
popular belief, VP is quite stereotypic in its presentation, and much 
of its reputation for presenting in vague and protean guises – and 
as psychiatric illness in particular – is erroneous, arising from the 
clinical description of patients who appear not to have had VP1,8,9 
(including, incidentally, the historical figure of King George III10,11).
Structural biochemistry
The ability to isolate and manipulate the PPOX gene has allowed 
us to perform useful work designed to elucidate the structure and 
function of both normal and mutant PPOX, including work on the 
Table 1. Summary of the haem biosynthetic enzymes and associated porphyrias
Enzyme Disorder Inheritance (predominant mode) Clinical features
ALA synthase X-linked protoporphyria (XLPP)
(additionally, sideroblastic 
anaemia)
X-linked Immediate photosensitivity; 
liver disease secondary to 
protoporphyrin accumulation
ALA dehydratase ALA dehydratase porphyria 
(ALADP)
Recessive Acute attacks
HMB synthase Acute intermittent porphyria 
(AIP)
Dominant Acute attacks
Uroporphyrinogen-III synthase Congenital erythropoietic 
porphyria (CEP)
Recessive Severe vesiculo-erosive skin disease
Uroporphyrinogen 
decarboxylase
Porphyria cutanea tarda (PCT) Acquired, but may be associated 
with a dominantly inherited 
mutation in approximately 30%
of cases
Vesiculo-erosive skin disease; 
usually coexists with iron overload 
and a number of precipitating 
factors, particularly alcohol 
exposure, liver disease and renal 
failure
Coproporphyrinogen oxidase Hereditary coproporphyria 
(HCP)
Dominant Acute attacks and vesiculo-erosive 
skin disease
Protoporphyrinogen oxidase Variegate porphyria (VP) Dominant Acute attacks and vesiculo-erosive 
skin disease
Ferrochelatase Erythropoietic protoporphyria 
(EPP)
Recessive, but more common than 
most recessive disorders since the 
disease-associated mutation is 
frequently inherited with a low-
expression polymorphism which 
is common in populations of 
European extraction
Immediate photosensitivity
ALA = δ-aminolaevulinic acid; HMB = hydroxymethylbilane.
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crystalline structure of PPOX, its mitochondrial targeting, expression 
studies of South Arican VP-associated mutations, expression of the 
R59W mutation in a knock-in mouse model and the tissue-specific 
expression of PPOX.
Drug porphyrogenicity
Avoidance of exposure to porphyrogenic medication is crucial to the 
control and prevention of the acute attack. Since Eales’s early career 
the group has continued to solicit, collate and collect clinical data 
on the outcomes of exposure to drugs in patients, more recently 
as part of an international collaboration centred on the European 
Porphyria Network (EPNET).† Our study of the safety of the injectable 
anaesthetic propofol in VP patients remains the only controlled trial 
of the safety of a drug in porphyria;12 it accompanies other reports on 
drug safety from our group, which are incorporated into a database 
established by the Norwegian Porphyria Association (NAPOS) in 
Bergen, Norway. This is international in scope, fully evidence-based, 
and premised on the application of predictive algorithms as well as 
the conventional descriptive (and thus retrospective) approach to 
the determination of porphyrogenicity. That it is web-based makes it 
accessible and of immediate benefit to the porphyria community. One 
of us (RJH) collaborates with the Scandinavian authors of this database 
in a state-of-the-art review of the science of drug porphyrogenicity.13
Patient management: diagnosis, treatment and education
Incorporation of our porphyria group within the Liver Research 
Centre resulted in close links between ourselves as porphyrinologists 
and the clinicians of the Liver Clinic at Groote Schuur Hospital, one of 
us (RJH) possessing expertise in both hepatology and porphyrinology. 
This facilitated the development of dedicated patient-centred services 
for consultation and management, both as in- and outpatients, 
while collaboration between the clinic and the laboratory promoted 
excellence in clinical management as well as relevant research. Young 
clinicians rotating through the clinic as medical registrars have 
become competent in porphyria management.
The work of the group is multidimensional, effective management 
of porphyria, demanding diagnosis, treatment and education of 
patient, family and healthcare professional(s). The diagnostic 
laboratory serves as the central reference laboratory for southern 
Africa, has a high throughput and diagnoses more cases of porphyria 
than any other laboratory in the world. In 2010, 718 individuals were 
investigated for porphyria, requiring some 2 007 individual analyses, 
since multiple biochemical and molecular tests on each individual 
are required to characterise the disorder fully. Diagnosis of 65 cases 
Fig. 1. Enzymes and metabolites of the haem biosynthetic pathway, located within the mitochondrion and the cytosol of a typical mammalian cell. ALAS = 
δ-aminolaevulinic acid synthase; ALAD = δ-aminolaevulinic acid dehydratase; HMBS = hydroxymethylbilane synthase; UROIIIS = uroporphyrinogen-III 
synthase; UROD = uroporphyrinogen decarboxylase; COP = coproporphyrinogen oxidase; PPOX = protoporphyrinogen oxidase; FECH = ferrochelatase; 
ALA = δ-aminolaevulinic acid; PBG = porphobilinogen. 
†EPNET is a network of expert porphyria centres providing specialist 
testing and clinical advice on all porphyrias. EPNET has expanded 
from 20 to 32 members in 21 countries (including 4 associate 
members from outside of Europe, one of which is the UCT group).
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of VP, 36 cases of PCT, 6 of acute intermittent porphyria (AIP), 3 of 
erythropoietic protoporphyria (EPP), 5 of X-linked protoporphyria 
and 1 of congenital erythropoietic porphyria was confirmed.
An effective modality for the treatment of skin disease in porphyria 
has proven elusive. We conducted a controlled trial of the use of oral 
activated charcoal in VP, with the hypothesis that the activated 
charcoal would interrupt the enterohepatic cycling of porphyrins, 
thus leading to a decrease in plasma porphyrins and decreased traffic 
of photoactive porphyrins into the skin. Paradoxically, we found that 
treatment caused deterioration. Nevertheless, by promoting careful 
and prudent skin care, most of our patients with VP enjoy a good 
quality of life.
Many consultations are for patients with PCT, a form of porphyria 
which typically is acquired, rather than inherited, and frequently 
precipitated by liver disease, that is associated with hepatic iron 
overload in particular. Close links between the porphyria group 
and the liver clinic promote expert and efficient investigation and 
management of the liver disease (including liver biopsy); this, 
together with a phlebotomy service established within the porphyria 
clinic, enables comprehensive patient care.
The most dramatic and dangerous manifestation of porphyria 
is the acute attack. We have one of the world’s largest experiences 
in management of this, and protocols we have developed are 
incorporated into international best practice.9,14
Introduction of intravenous haem-containing compounds for the 
management of the acute attack was pivotal in improving outcomes.15 
Augmented hepatocellular haem concentrations repress ALA synthase 
by a negative feedback mechanism, thus dramatically reducing 
porphyrin synthesis, halting the acute attack and preventing the 
onset of serious complications. Haem arginate (Normosang, Orphan 
Europe), is available to South African patients through our arranging 
for its importation and registration. Similarly South African patients 
with EPP have access to beta-carotene and canthaxanthine, agents 
which, in high doses, may ameliorate the severe photosensitivity 
associated with the condition.
We have been vigorous in advocacy for the porphyria community 
and have been active in educating patients, families, health 
professionals and the public about porphyria and its management. 
Booklets and information sheets on the subject have been published 
and incorporated into a range of media resources and a website has 
been established with full information on the care of porphyria and the 
safe prescription of drugs. A Porphyria Information Centre, offering 
a walk-in/phone-in service for patients and health professionals, has 
been set up. 
Other forms of porphyria: experience and research
Not restricted to VP, the clinic regularly diagnoses, manages and 
studies patients with less common forms of porphyria (and many 
of our publications reflect this). PCT is not uncommon in South 
Africa, and useful research was conducted by Eales, Sweeney, 
Blekkenhorst and Pimstone,16 and more recently by the present 
authors. Sweeney was one of the first to methodically assess the 
use of chloroquine in the treatment of PCT. Subsequently we have 
investigated the association of PCT with liver disease and with viral 
hepatitis and iron overload in particular. More recently we have 
been studying the association between PCT and HIV.
Although AIP is considerably less prevalent in South Africans 
than VP, it accounts for the majority of the acute attacks treated.9 
We have participated in molecular studies of AIP in South Africa, 
delineating the spectrum of mutations in the hydroxymethylbilane 
synthase gene which underlie this disorder.17 In EPP, we conducted 
a national study in affected South African families and identified 
18 families carrying 4 mutations, 12 of whom carried the same 
mutation and were shown by haplotype analysis to have a common 
ancestor.18 One family proved particularly interesting in that the 
clinical features were atypical and we were unable to identify any 
mutation in the ferrochelatase gene as would be expected. This South 
African family, and several others in Europe, were shown to have a 
novel disease now termed X-linked protoporphyria.19 This arises 
pathogenetically from a gain-of-function mutation in the erythroid 
form of ALA synthase, which results in a greatly increased flux of 
porphyrins through the haem biosynthetic pathway; ferrochelatase 
becomes rate-limiting (probably at the level of iron availability) and 
free and zinc protoporphyrin accumulates, hence the resemblance 
to classic EPP, where the accumulation of protoporphyrin is caused 
by an inherited deficiency of ferrochelatase. There appears to be a 
high incidence of protoporphyria-associated liver disease in these 
families, a feature noted by Eales in the late 1970s.
A further interest has been the study of those rare patients 
with unusual – and usually severe – presentations arising from 
homozygosity or compound heterozygosity for porphyria-
associated mutations. We have studied patients with congenital 
erythropoietic porphyria and hepato-erythropoietic porphyria, 
arising from double defects in the enzymes uroporphyrinogen 
cosynthase and uroporphyrinogen decarboxylase respectively, as 
well as homozygous VP. Given the high prevalence of VP in 
South Africa, homozygotes would be expected to be commonly 
encountered. In practice this has not been the case, leading us to 
hypothesise, along with others, that the homozygous condition 
is lethal. Our work on the expression of VP-associated PPOX 
mutations in cell culture, as well as studies in a knock-in mouse 
model which expresses the R59W mutation,20 have confirmed this. 
The R59W mutation results in a defective enzyme with effectively 
zero kinetic activity, and homozygosity for this condition is lethal 
since no haem synthesis is possible. Indeed, in the mouse model, 
homozygous offspring do not survive beyond the ninth day after 
conception. We have identified 4 young patients with apparent 
homozygous VP, and shown that, rather than being homozygotes, 
they are compound heterozygotes, carrying the R59W mutation on 
one allele, but an unrelated mutation on the other.2 In expression 
systems, additional mutations were shown to encode PPOX proteins 
with some residual enzymatic activity; it is this activity that keeps 
the patient alive.
Conclusion
In the past half-century the porphyria group has made significant 
contributions to the research of porphyrins, porphyrias and haem 
biosynthesis, matched by holistic and comprehensive care for 
patients.
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